Provided by Tiger Trade Technology Pte. Ltd.

LivaNova PLC

62.19
-1.3400-2.11%
Post-market: 61.93-0.2600-0.42%18:03 EDT
Volume:1.21M
Turnover:75.11M
Market Cap:3.40B
PE:-13.98
High:63.87
Open:63.37
Low:61.47
Close:63.53
52wk High:71.92
52wk Low:32.48
Shares:54.61M
Float Shares:54.41M
Volume Ratio:1.36
T/O Rate:2.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.4500
EPS(LYR):-4.4500
ROE:-19.24%
ROA:5.17%
PB:2.83
PE(LYR):-13.98

Loading ...

LivaNova Outlook FY Adjusted EPS USD 4.15-4.25

THOMSON REUTERS
·
Feb 25

Press Release: LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance

Dow Jones
·
Feb 25

Piper Sandler Sticks to Their Buy Rating for LivaNova (LIVN)

TIPRANKS
·
Feb 19

Earning Preview: LivaNova PLC this quarter’s revenue is expected to increase by 9.03%, and institutional views are Hold

Earnings Agent
·
Feb 18

A Look At LivaNova (LIVN) Valuation After KeyBanc Upgrade And Renewed Medtech Optimism

Simply Wall St.
·
Feb 03

Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NKTR) and LivaNova (LIVN)

TIPRANKS
·
Jan 26

LivaNova plc to Announce Fourth-Quarter and Full-Year Results

Reuters
·
Jan 20

LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results

THOMSON REUTERS
·
Jan 20

LivaNova Chief Legal Officer Michael Hutchinson Resigns

Reuters
·
Jan 14

LivaNova (LIVN) Is Up 6.2% After Fresh Analyst Optimism on Advanced Therapies Portfolio - What's Changed

Simply Wall St.
·
Jan 11

LivaNova Is Maintained at Equal-Weight by Barclays

Dow Jones
·
Jan 09

LivaNova price target raised to $66 from $56 at Goldman Sachs

TIPRANKS
·
Jan 09

Barclays Reaffirms Their Hold Rating on LivaNova (LIVN)

TIPRANKS
·
Jan 09

LivaNova (LIVN): Reassessing Valuation After KeyBanc’s Overweight Initiation and Growth Outlook

Simply Wall St.
·
Dec 22, 2025

KeyBanc Initiates LivaNova at Overweight With $81 Price Target

MT Newswires Live
·
Dec 19, 2025

LivaNova Initiated at Overweight by Keybanc

Dow Jones
·
Dec 19, 2025

LivaNova Plc : Keybanc Initiates Coverage With Overweight Rating and Target Price $81

THOMSON REUTERS
·
Dec 19, 2025

Assessing LivaNova (LIVN)’s Valuation After Hiring ResMed Veteran to Lead Sleep Apnea Commercialization

Simply Wall St.
·
Dec 15, 2025

The Bull Case For LivaNova (LIVN) Could Change Following Medicare VNS Boost And New OSA Leader

Simply Wall St.
·
Dec 09, 2025

LivaNova Highlights CORE-VNS Study Showing VNS Therapy Reduces Seizure Frequency and Healthcare Costs in Drug-Resistant Epilepsy

Reuters
·
Dec 03, 2025